Evidence map›Paper›PMID 38946967›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.

Mohammed Nooruzzaman, Katherine E E Johnson, Ruchi Rani, Eli J Finkelsztein, Leonardo C Caserta, Rosy P Kodiyanplakkal, Wei Wang, Jingmei Hsu, Maria T Salpietro, Stephanie Banakis and 8 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Mohammed NooruzzamanDepartment of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University.ORCID 0000-0002-9358-1494
Katherine E E JohnsonSystems Genomics Section, NIH/NIAID/DIR/LPD.
Ruchi RaniDepartment of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University.
Eli J FinkelszteinDepartment of Medicine, Weill Cornell Medicine.
Leonardo C CasertaDepartment of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University.
Rosy P KodiyanplakkalDepartment of Medicine, Weill Cornell Medicine.
Wei WangSystems Genomics Section, NIH/NIAID/DIR/LPD.
Jingmei HsuDepartment of Medicine, Weill Cornell Medicine.
Maria T SalpietroInstitutional Biorepository Core, Weill Cornell Medicine.
Stephanie BanakisSystems Genomics Section, NIH/NIAID/DIR/LPD.
Joshua AlbertSystems Genomics Section, NIH/NIAID/DIR/LPD.
Lars WestbladeDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine.
Claudio ZanettiniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine.
Luigi MarchionniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine.
Rosemary SoaveDepartment of Medicine, Weill Cornell Medicine.
Elodie GhedinSystems Genomics Section, NIH/NIAID/DIR/LPD.ORCID 0000-0002-1515-725X
Diego G DielDepartment of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University.ORCID 0000-0003-3237-8940
Mirella SalvatoreDepartment of Medicine, Weill Cornell Medicine.

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Novel diagnostic tools and animal model system for study human/animal interface of COVID-19R01AI166791 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI DIEL, DIEGO G, FANG, YING · 2021 to 2024
$3.1M
Determining factors of transmission and evolution of SARS-CoV-2 in populations at risk ZIAAI001324 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GHEDIN, ELODIE · 2020 to 2025
$2.7M
NCATS NIH HHS UL1 TR002384NIAID NIH HHS R01 AI166791
6 · The paper itself

Abstract

We investigated the impact of antiviral treatment on the emergence of SARS-CoV-2 resistance during persistent infections in immunocompromised patients (n=15). All patients received remdesivir and some also received nirmatrelvir-ritonavir or monoclonal antibodies. Sequence analysis showed that nine patients carried viruses with mutations in the nsp12 (RNA dependent RNA polymerase), while four had viruses with nsp5 (3C protease) mutations. Infectious SARS-CoV-2 with a double mutation in nsp5 (T169I) and nsp12 (V792I) was recovered from respiratory secretions 77 days after initial COVID-19 diagnosis from a patient treated with remdesivir and nirmatrelvir-ritonavir.

Identifiers

PMID38946967
PMCPMC11213110

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.